CN Patent

CN112512530A — 使用达格列净和包含达格列净的组合物治疗HFpEF的方法

Assigned to AstraZeneca AB · Expires 2021-03-16 · 5y expired

What this patent protects

披露了通过使用达格列净和包含达格列净的组合物治疗和/或预防患者的HFpEF和/或与之相关的至少一种疾病、障碍和/或病症的方法。

USPTO Abstract

披露了通过使用达格列净和包含达格列净的组合物治疗和/或预防患者的HFpEF和/或与之相关的至少一种疾病、障碍和/或病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112512530A
Jurisdiction
CN
Classification
—
Expires
2021-03-16
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.